Alpha 2.0
Login Register
» Articles » PMID: 16882698

Squamous Differentiation in Primary Urothelial Carcinoma of the Urinary Tract As Seen by MAC387 Immunohistochemistry

Overview
Journal J Clin Pathol
Specialty Pathology
Date 2006 Aug 3
PMID 16882698
Citations 20
Authors
Antonio Lopez-Beltran
Maria J Requena
Jose Alvarez-Kindelan
Ana Quintero
Ana Blanca
Rodolfo Montironi
Affiliations
Soon will be listed here.
Abstract

Squamous differentiation (SqD) is variably present in urinary tract tumours, but its significance remains unclear. In this study, SqD was assessed by immunohistochemistry using the monoclonal antibody Mac387 in 145 urothelial tumours (bladder, n = 115; renal pelvis, n = 30). Mac387 detects the myelomonocytic L1 antigen; a member of the calgranulin family shared by epithelial cells and keratinocytes. L1 antigen was shown in SqD in urothelial carcinomas of the bladder or the renal pelvis, including 11 cases with focal SqD unrecognised by conventional analysis. SqD is more frequent in renal pelvic tumours (p = 0.027) and increases with grade/stage mainly in bladder carcinoma (grade, p = 0.05; stage, p = 0.005). Stage Ta/T1 bladder carcinomas with SqD recurred more (p = 0.021). In conclusion, Mac387 efficiently shows SqD in urothelial tumours.

Citing Articles

The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.

Huang L, Chen C, Li J, Chiu K, Wang S, Yang C BMC Cancer. 2024; 24(1):247.

PMID: 38388388 PMC: 10885513. DOI: 10.1186/s12885-024-12010-5.

Clinical features of patients with -deleted bladder cancer.

De Souza A, Mega A, Douglass J, Olszewski A, Gamsiz Uzun E, Uzun A Am J Cancer Res. 2023; 13(1):326-339.

PMID: 36777505 PMC: 9906077.

Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma.

Miyama Y, Kaneko G, Nishimoto K, Yasuda M Cancer Med. 2022; 11(22):4236-4245.

PMID: 35699000 PMC: 9678108. DOI: 10.1002/cam4.4779.

Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer-narrative review.

Piszczek R, Krajewski W, Moschini M, Kolodziej A, Nowak L, Poterek A Transl Cancer Res. 2022; 9(11):7323-7336.

PMID: 35117333 PMC: 8798016. DOI: 10.21037/tcr-20-2257.

Urethral squamous papilloma with multiple bladder diverticulum: A case report and literature review.

Sengupta S, Basu S, Ghosh K, Sengupta S Urol Case Rep. 2021; 37:101638.

PMID: 33816120 PMC: 8005749. DOI: 10.1016/j.eucr.2021.101638.

References
1.
Logothetis C, Dexeus F, Chong C, Sella A, Ayala A, Ro J . Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol. 1989; 141(1):33-7. DOI: 10.1016/s0022-5347(17)40578-7. View
2.
Sanchez-Carbayo M, Socci N, Charytonowicz E, Lu M, Prystowsky M, Childs G . Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002; 62(23):6973-80. View
3.
Honma I, Masumori N, Sato E, Takayanagi A, Takahashi A, Itoh N . Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology. 2004; 64(4):744-8. DOI: 10.1016/j.urology.2004.05.003. View
4.
Martin J, Jenkins B, Zuk R, Blandy J, Baithun S . Clinical importance of squamous metaplasia in invasive transitional cell carcinoma of the bladder. J Clin Pathol. 1989; 42(3):250-3. PMC: 1141863. DOI: 10.1136/jcp.42.3.250. View
5.
Harnden P, Southgate J . Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol. 1998; 50(12):1032-3. PMC: 500388. DOI: 10.1136/jcp.50.12.1032. View